Liquid chromatographic assay for the cyclic depsipeptide aplidine, a new marine antitumor drug, in whole blood using derivatization with trans-4′-hydrazino-2-stilbazole

Biomedical Chromatography

Volumn 18, Issue 1, 2004, Pages 16-20

  Sparidans, Rolf W ^a   Schellens, Jan H M ^a   López Lázaro, Luis ^b   Jimeno, José M ^b   Beijnen, Jos H ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b PHARMAMAR S A   (Spain)

Author keywords

Aplidine; Dehydrodidemnin B; Depsipeptide; Marin compound; Trans 4 hyrazino 2 stilbazole; Whole blood

Indexed keywords

BLOOD; FLUORESCENCE; LIQUID CHROMATOGRAPHY; PHASE SEPARATION; PLASMA STABILITY; SILICA;

ANALYTES; APLIDINE; DEHYDRODIDEMNIN B; DEPSIPEPTIDES; DERIVATIZATIONS; FLUORESCENCE DETECTION; MARIN COMPOUND; STILBAZOLE; TRANS-4′-HYRAZINO-2-STILBAZOLE; WHOLE BLOOD;

ACETONE;

4' HYDRAZINO 2 STILBAZOLE; ACETONE; ACETONITRILE; ANTINEOPLASTIC AGENT; CYCLODEPSIPEPTIDE; DEHYDRODIDEMNIN B; PYRROLE DERIVATIVE; SILICON DIOXIDE; UNCLASSIFIED DRUG; WATER;

ACCURACY; ARTICLE; BIOASSAY; BLOOD SAMPLING; CALCULATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DERIVATIZATION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG STRUCTURE; EVAPORATION; EXCITATION; FLUORESCENCE ANALYSIS; PH; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; REVERSED PHASE LIQUID CHROMATOGRAPHY; SENSITIVITY ANALYSIS; SOLID PHASE EXTRACTION; VALIDATION PROCESS;

EID: 1142287460     PISSN: 02693879     EISSN: None     Source Type: Journal    
DOI: 10.1002/bmc.286     Document Type: Article

References (17)

1. Armand JP, Ady-Vago N, Faivre S, Chieze S, Baudin E, Ribrag V, Lecot F, Iglesias L, Lopez-Lazaro L, Guzmán C, Jimeno J, Ducreux M, Le Chevalier T and Raymond E. Phase I pharmacokinetic study of aplidine given as a 24-hour continuous infusion every other week in patients with solid tumour and lymphoma. ASCO Meeting proceedings, San Francisco, 2001, abstract 477.
2. Bowman A, Izquierdo M, Jodrell D, Martinez M, Cicchella B, Jimeno J, Guzman C, Germa-Lluch J, Celli N and Smyth J. Phase I clinical and pharmacokinetic study of the marine compound aplidine, administered als a 1 hour weekly infusion. ASCO Meeting proceedings, San Francisco, 2001, abstract 476.
3. Celli N, Gallardo AM, Rossi C, Zucchetti M, D'Incalci M and Rotilio D. Analysis of aplidine (dehydrodidemnin B), a new marine-derived depsipeptide, in rat biological fluids by liquid chromatogrphy-tandem mass spectrometry. Journal of Chromatography B 1999; 731: 335.
4. Crumb WJ and Faircloth GT. Aplidine as an L-type calcium channel enhancer. Patent WO 98/50048, 1998.
5. Depenbrock H, Peter R, Faircloth GT, Manzanares I, Jimeno J and Hanauske AR. In vitro activity of aplidine, a new marine-derived anti-cancer compound, on freshly explanted clonogenic human tumour Cells and hemapoetic precursor cells. British Journal of Cancer 1998; 78: 739.
6. Geldof AA, Mastbergen SC, Henrar REC and Faircloth GT. Cytotoxicity and neurotoxicity of new marine anticancer agents evaluated using in vitro assays. Cancer Chemotherapy and Pharmacology 1999; 44: 312.
7. Gómez-Fabre PM, de Pedro E, Medina MA, Núñez de Castro I and Márquez J. Polyamine contents of human breast cancer cells treated with the cytotoxic agents chlorpheniramine and dehydrodidemnin B. Cancer Letters 1997; 113: 141.
8. Lobo C, García-Pozo SG, Núñez de Castro I and Alonzo FJ. Effect of dehydrodidemnin B on human colon carcinoma cell lines. Anticancer Research 1997; 17: 333.
9. Maroun JA, Goel R, Stewart DJ, Tomiak E, Belanger K, Soulieres D, Charpentier D, Seymour L, Matthews S, Jimeno J, Guzman C, ASCO Meeting Proceedings, San Francisco, 2001, abstract 2082.
10. Paz-Ares L, Anthony A, Pronk L, Twelves C, Alonso S, Cortes-Funes H, Celli N, Gomez C, López-Lázaro L, Guzman C, Jimeno J and Kaye S. Phase I clinical and pharmacokinetic study of aplidine, a new marine didemnin, administered as a 24-hour infusion weekly. NCI-EORTC-AACR Conference Proceedings, Amsterdam, 2000, abstract 217.
11. Rinehart KL. Antitumor compounds from tunicates. Medical Research Review 2000; 20: 1.
12. Rosing H, Man WY, Doyle E, Bult A and Beijnen JH. Bioanalytical chromatographic method validation. A review of current practices and procedures. Journal of Liquid Chromatography and Related Technology 2000; 23: 329.
13. Sakai R, Rinehart KL, Kishore V, Faircloth G, Gloer JB, Carney JR, Namikoshi M, Sun F, Hughes RG, Jr., García Grávalos D, García de Quesada T and Wilson GR. Structure-activity relationships of the didemnins. Journal of Medical Chemistry 1996; 39: 2819.
14. Shah VP, Midha KK, Dighe S, McGliveray IJ, Skelly JP, Jacobi A, Layloff T, Viswanathan CT, Cook CE, McDowall RD, Pittman KA and Spector S. Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Journal of Pharmaceutical Science 1992; 81: 309.
15. Sparidans RW, Kettenes-van den Bosch JJ, van Tellingen O, Nuyen B, Henrar REC, Jimeno JM, Faircloth G, Floriano P, Rinehart KL and Beijnen JH. Bioanalysis of aplidine, a new antitumoral depsipeptide, in plasma by high-performance liquid chromatography after derivatization with trans-4′-hydrazino-2-stilbazole. Journal of Chromatography B 1999; 729: 43.
16. Urdiales JL, Morata P, Núñez De Castro I and Sánchez-Jiménez F. Antiproliferative effect of dehydrodidemnin B, a depsipeptide isolated from Mediterranean tunicates. Cancer Letters 1996; 102: 31.
17. Zucchetti M, Lopez-Lazaro L, Celli N, Cicchella B, Twelves CT, Paz-Ares L, Izquierdo MA, Bowman A, Raymond E, Maroun J, Belanger K and D'Incalci M. Clinical pharmacokinetics of aplidine in patients with solid tumors and non-hodgkin lymphomas. Proceedings of the 91st Annual Meeting of the AACR, San Francisco, 2000, abstract 4932.